Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Immunic CEO talks BIO-Europe 2025, MS trials, and IMU-856
MP3•Episode home
Manage episode 518246059 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. The conversation centred on the progress of its lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for relapsing multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026. Vitt described the Vienna-based conference as “a very exciting, active, energetic meeting” and highlighted its international scope. He noted that while Immunic is US-focused, BIO-Europe provided valuable networking opportunities within the European investor and biotech community. Much of the investor and partner interest at the event was directed towards Immunic’s multiple sclerosis program. “It’s a unique growth story and has the ability to address here a multi-billion market opportunity,” said Vitt, referring to vidofludimus calcium, which he described as “a dual acting molecule” and “first in class Nurr-1 activator.” In addition, Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which has shown promising early clinical data in celiac disease and GLP-1 upregulation. The company is exploring further development and potential partnerships for this asset. For more biotech updates and executive insights, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel and enable notifications for future content. #Immunic #MultipleSclerosis #VidofludimusCalcium #IMU856 #BiotechNews #BIOEurope2025 #ClinicalTrials #PharmaUpdate #CeliacDisease #MSResearch #HealthcareInvesting
…
continue reading
608 episodes
MP3•Episode home
Manage episode 518246059 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. The conversation centred on the progress of its lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for relapsing multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026. Vitt described the Vienna-based conference as “a very exciting, active, energetic meeting” and highlighted its international scope. He noted that while Immunic is US-focused, BIO-Europe provided valuable networking opportunities within the European investor and biotech community. Much of the investor and partner interest at the event was directed towards Immunic’s multiple sclerosis program. “It’s a unique growth story and has the ability to address here a multi-billion market opportunity,” said Vitt, referring to vidofludimus calcium, which he described as “a dual acting molecule” and “first in class Nurr-1 activator.” In addition, Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which has shown promising early clinical data in celiac disease and GLP-1 upregulation. The company is exploring further development and potential partnerships for this asset. For more biotech updates and executive insights, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel and enable notifications for future content. #Immunic #MultipleSclerosis #VidofludimusCalcium #IMU856 #BiotechNews #BIOEurope2025 #ClinicalTrials #PharmaUpdate #CeliacDisease #MSResearch #HealthcareInvesting
…
continue reading
608 episodes
Alla avsnitt
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.